Journal Article
. 2017 Sep;77(9).
doi: 10.1055/s-0043-115396.

How Do Patients Experience Individualized Medicine? A Qualitative Interview-based Study of Gene Expression Analyses in the Treatment of Breast Cancer

Sebastian Schleidgen 1 Sandra Thiersch 2 Rachel Wuerstlein 3 Georg Marckmann 2 
Affiliations
  • PMID: 28959062
  •     19 References
  •     2 citations

Abstract

Introduction: In recent years, the hopes and expectations associated with so-called individualized medicine have been the subject of intense debate as has the medical potential of this approach. Questions about the uses of gene expression analyses for decisions on adjuvant systemic treatment options for patients with breast cancer have played a prominent role in this debate. There are a number of empirical studies on the effect of gene expression tests on the therapy decisions of physicians and the potentially conflicted decisions for patients. Very little attention has been paid to how patients perceive such approaches, the extent to which they feel included in the therapy decision, and the expectations they associate with such an approach.

Material And Methods: Using qualitative explorative interviews, the study looked at how well patients with breast cancer understood the individualized treatment approaches and examined patients' experiences and expectations with regard to gene expression analyses. The sample consisted of 8 patients who were diagnosed with primary hormone receptor-positive, HER2-negative breast cancer between 2013 and 2014 and who underwent gene expression analyses as part of their adjuvant therapy planning.

Results: Patients were found to have a quite realistic view of the benefits of gene expression analyses, although it also became clear that the treatment could also raise false hopes. The statements by the interviewed women also illustrated the necessity of continuing to explore the possibilities and limits to joint decision-making in such complex medical contexts as individualized molecular genomic medicine. And finally, the interviews reflected the hope for individualized treatment in the broadest sense of the word.

Conclusion: The results of the study highlight the challenge of taking psychosocial aspects of medical treatment sufficiently into consideration, given the ever increasing options for molecular genomic individualization.

Keywords: gene expression analyses; joint decision-making; medical benefit; molecular genomic individualization.

Prospective medicine: the next health care transformation.
Ralph Snyderman, R Sanders Williams.
Acad Med, 2003 Nov 08; 78(11). PMID: 14604864
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review.
J D Tariman, D L Berry, +2 authors, K Schepp.
Ann Oncol, 2009 Nov 27; 21(6). PMID: 19940010    Free PMC article.
Systematic Review.
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Michael Knauer, Stella Mook, +7 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2010 Mar 06; 120(3). PMID: 20204499
Preferred roles in treatment decision making among patients with cancer: a pooled analysis of studies using the Control Preferences Scale.
Jasvinder A Singh, Jeff A Sloan, +7 authors, Lesley F Degner.
Am J Manag Care, 2010 Sep 30; 16(9). PMID: 20873956    Free PMC article.
P5 medicine: a plus for a personalized approach to oncology.
Alessandra Gorini, Gabriella Pravettoni.
Nat Rev Clin Oncol, 2011 Jun 02; 8(7). PMID: 21629214
A P5 cancer medicine approach: why personalized medicine cannot ignore psychology.
Gabriella Pravettoni, Alessandra Gorini.
J Eval Clin Pract, 2011 Jun 18; 17(4). PMID: 21679280
[Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study].
Regine Wolters, Achim Wöckel, Manfred Wischnewsky, Rolf Kreienberg.
Z Evid Fortbild Qual Gesundhwes, 2011 Aug 17; 105(6). PMID: 21843852
Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes.
Richard Brown, Phyllis Butow, +3 authors, Ilona Juraskova.
J Clin Oncol, 2012 Feb 09; 30(8). PMID: 22312102
[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Wolf-Dieter Ludwig.
Z Evid Fortbild Qual Gesundhwes, 2012 Feb 14; 106(1). PMID: 22325103
Review.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Balancing personalized medicine and personalized care.
Kenneth Cornetta, Candy Gunther Brown.
Acad Med, 2013 Jan 26; 88(3). PMID: 23348082    Free PMC article.
Medicine. (De)personalized medicine.
Ralph I Horwitz, Mark R Cullen, Jill Abell, Jennifer B Christian.
Science, 2013 Mar 09; 339(6124). PMID: 23471391
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
What is personalized medicine: sharpening a vague term based on a systematic literature review.
Sebastian Schleidgen, Corinna Klingler, +2 authors, Georg Marckmann.
BMC Med Ethics, 2013 Dec 24; 14. PMID: 24359531    Free PMC article.
Systematic Review.
Personalized health care as a pathway for the adoption of genomic medicine.
Robin Burnette, Leigh Ann Simmons, Ralph Snyderman.
J Pers Med, 2012 Jan 01; 2(4). PMID: 25562362    Free PMC article.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
R Wuerstlein, K Sotlar, +17 authors, N Harbeck.
Curr Med Res Opin, 2016 Mar 15; 32(7). PMID: 26971372
Improving the quality of 'personalized medicine' research and practice: through an ethical lens.
George P Browman, Jochen Vollmann, Alice Virani, Jan Schildmann.
Per Med, 2014 Jun 01; 11(4). PMID: 29783476
Psycho-oncology care in breast cancer centres: a nationwide survey.
Nicole Ernstmann, Anna Enders, +4 authors, Franziska Geiser.
BMJ Support Palliat Care, 2019 Apr 15; 10(4). PMID: 30981992    Free PMC article.
A Network-Based Mixed Methods Approach to Analyze Current Perspectives on Personalized Oncological Medicine in Austria.
Ines Viktoria Stelzer, Anna Sierawska, Alena Buyx, Judit Simon.
J Pers Med, 2020 Dec 17; 10(4). PMID: 33322735    Free PMC article.